Australia's Healius rises on sale of unit Agilex Biolabs to Novotech Health

By Reuters News

** Shares of Australia's Healius HLS.AX rise as much as 18.1% to A$0.425, their biggest intraday gain since August 20

** Stock hits highest level since September 18

** Healthcare firm agrees to sell its unit Agilex Biolabs to subsidiary of Novotech Health for enterprise value of A$160 million ($112.06 million)

** Expects cash proceeds of A$155 million after costs

** Says Agilex Biolabs' disposal at a sufficiently attractive price would unlock value for shareholders and support management focus on ongoing growth of Healius' core Pathology business.

** Stock down 55.8% YTD

($1 = 1.4278 Australian dollars)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.